Results 41 to 50 of about 1,998,403 (289)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

open access: yesKidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy   +2 more
doaj   +1 more source

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

open access: yesPulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam   +6 more
doaj   +1 more source

Operative management of immune checkpoint colitis following in-transit melanoma: Case report

open access: yesFrontiers in Oncology, 2023
Immune checkpoint inhibitors are increasingly used as powerful anti-neoplastic therapies in the setting of melanoma. Colitis is a known complication of immune checkpoint inhibitors that if often medically managed.
Betzaira G. Childers   +5 more
doaj   +1 more source

Research Progress of Immune Checkpoint Inhibitors in Colorectal Cancer

open access: yesZhongliu Fangzhi Yanjiu, 2020
Tumor immunity is a new line of research for the treatment of patients with solid tumors, and negative regulators of the immune system called immune checkpoints play a key role in limiting antitumor immunologic responses.
ZHUANG Yuwen   +3 more
doaj   +1 more source

Research Progress of Immune Checkpoint Therapy on Colorectal Cancer

open access: yesZhongliu Fangzhi Yanjiu, 2021
At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj   +1 more source

Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

open access: yesБезопасность и риск фармакотерапии, 2020
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1), has improved the prognosis of ...
E. V. Shubnikova   +4 more
doaj   +1 more source

Cardiotoxicity Associated with Immune Checkpoint Inhibitors

open access: yes, 2023
Immune checkpoint inhibitors (ICIs) have shown significant efficacy in various cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial cancer, and ...
Kiyoshi Hibi   +3 more
core   +1 more source

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

open access: yesFrontiers in Immunology, 2017
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher   +7 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

open access: yesCancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

Immune Checkpoint Inhibitors in Prostate Cancer

open access: yes, 2021
Metastatic prostate cancer is a lethal disease with limited treatment options. Immune checkpoint inhibitors have dramatically changed the treatment landscape of multiple cancer types but have met with limited success in prostate cancer.
Taylor R. McFarland   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy